Reply to “Survival of expanded dopaminergic precursors is critical for clinical trials” (original) (raw)

Nature Neuroscience volume 1, page 537 (1998)Cite this article

REPLY - We recognize the important contributions made by the Swedish groups in Lund and Stockholm to cell therapy for Parkinson's disease and welcome the opportunity to respond to the letter from Drs. Brundin and Björklund. There are several sites where grafting technology can be optimized: precursor cell expansion, neuronal survival and functional integration in vivo.

Our recently published work1 is directed at the first of these issues and makes one specific claim—that functional dopaminergic neurons can be derived from in vitro expanded precursors. There are 30,000 tyrosine hydroxylase-positive (TH+) neurons in the adult rat substantia nigra6. We show that 200,000 precursor-derived TH+ neurons can be obtained per embryo in vitro and that these neurons synthesize and release dopamine in response to depolarization. We also show in vivo that 1,200 TH+ neurons survive from an initial graft of 40,000 TH+ neurons and that these cells lead to functional recovery. Further studies will be needed to compare directly the in vivo survival of dopaminergic neurons derived from expanded precursors with that of primary cell grafts. Historical comparisons are problematic, especially as the studies cited in the above letter3,4 analyzed graft survival 1–6 weeks after transplantation, whereas our study focused on more long-term survival (three months). Although several other studies2,7,8 also claim that TH+ cells can be obtained in culture, our data demonstrate, with in vitro and in vivo measures, that functional dopaminergic neurons can indeed be derived from expanded precursors.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Studer, L., Tabar, V. & McKay R. D. G. Nature Neurosci. 1, 290– 295 (1998).
    Article CAS Google Scholar
  2. Bouvier, M. M. & Mytilineou, C. J. Neurosci. 15, 7141–7149 (1995).
    Article CAS Google Scholar
  3. Zawada, W. M. et al. Brain Res. 786, 96– 103 (1998).
    Article CAS Google Scholar
  4. Nakao, N., Frodl, E. M., Duan, W.-M., Widner, H. & Brundin, P. Proc. Natl. Acad. Sci. USA 91, 12408–12412 (1994).
    Article CAS Google Scholar
  5. Rosenblad, C, Martinez-Serrano, A. & Björklund, A., Neuroscience 75, 979–985 (1996).
    Article CAS Google Scholar
  6. Rosenthal, A. Neuron 20, 169–172 ( 1998).
    Article CAS Google Scholar
  7. Ling, Z. D., Potter, E. D., Lipton, J. W. & Carvey, P. M. Exp. Neurol. 149, 411–423 (1998).
    Article CAS Google Scholar
  8. Du, X., Stull, N. D. & Iacovitti, L. J. Neurosci. 14, 7688– 7694 (1994).
    Article CAS Google Scholar

Download references

Author information

Authors and Affiliations

  1. Laboratory of Molecular Biology, NINDS, NIH, 36 Convent Drive, Building 36, Room 5A29, Bethesda, 20892, Maryland, USA
    Lorenz Studer, Viviane Tabar & Ronald McKay

Authors

  1. Lorenz Studer
    You can also search for this author inPubMed Google Scholar
  2. Viviane Tabar
    You can also search for this author inPubMed Google Scholar
  3. Ronald McKay
    You can also search for this author inPubMed Google Scholar

Rights and permissions

About this article

Cite this article

Studer, L., Tabar, V. & McKay, R. Reply to “Survival of expanded dopaminergic precursors is critical for clinical trials”.Nat Neurosci 1, 537 (1998). https://doi.org/10.1038/2774

Download citation